Oncolytic adenovirus: A tool for reversing the tumor microenvironment and promoting cancer treatment (Review)
- Authors:
- Xiaoxi Wang
- Liping Zhong
- Yongxiang Zhao
-
Affiliations: National Center for International Research of Biological Targeting Diagnosis and Therapy, Guangxi Key Laboratory of Biological Targeting Diagnosis and Therapy Research, Collaborative Innovation Center for Targeting Tumor Diagnosis and Therapy, Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region 530021, P.R. China - Published online on: March 2, 2021 https://doi.org/10.3892/or.2021.8000
- Article Number: 49
-
Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
This article is mentioned in:
Abstract
 |
 |
|
Giraldo NA, Sanchez-Salas R, Peske JD, Vano Y, Becht E, Petitprez F, Validire P, Ingels A, Cathelineau X, Fridman WH and Sautès-Fridman C: The clinical role of the TME in solid cancer. Br J Cancer. 120:45–53. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Chen Y, Liu J, Wang W, Xiang L, Wang J, Liu S, Zhou H and Guo Z: High expression of hnRNPA1 promotes cell invasion by inducing EMT in gastric cancer. Oncol Rep. 39:1693–1701. 2018.PubMed/NCBI | |
|
Choi J, Gyamfi J, Jang H and Koo JS: The role of tumor-associated macrophage in breast cancer biology. Histol Histopathol. 33:133–145. 2018.PubMed/NCBI | |
|
Sun Y: Tumor microenvironment and cancer therapy resistance. Cancer Lett. 380:205–215. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Akbulut H, Coleri A, Sahin G, Tang Y and Icli F: A bicistronic adenoviral vector carrying cytosine deaminase and granulocyte-macrophage colony-stimulating factor increases the therapeutic efficacy of cancer gene therapy. Hum Gene Ther. 30:999–1007. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Ashshi AM, El-Shemi AG, Dmitriev IP, Kashentseva EA and Curiel DT: Combinatorial strategies based on CRAd-IL24 and CRAd-ING4 virotherapy with anti-angiogenesis treatment for ovarian cancer. J Ovarian Res. 9:382016. View Article : Google Scholar : PubMed/NCBI | |
|
Athanasopoulos T, Munye MM and Yanez-Munoz RJ: Nonintegrating gene therapy vectors. Hematol Oncol Clin North Am. 31:753–770. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Salzman R, Cook F, Hunt T, Malech HL, Reilly P, Foss-Campbell B and Barrett D: Addressing the value of gene therapy and enhancing patient access to transformative treatments. Mol Ther. 26:2717–2726. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Stasiak AC and Stehle T: Human adenovirus binding to host cell receptors: A structural view. Med Microbiol Immunol. 209:325–333. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Greber UF and Flatt JW: Adenovirus entry: From infection to immunity. Annu Rev Virol. 6:177–197. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Hoeben RC and Uil TG: Adenovirus DNA replication. Cold Spring Harb Perspect Biol. 5:a0130032013. View Article : Google Scholar : PubMed/NCBI | |
|
Gao J, Zhang W and Ehrhardt A: Expanding the spectrum of adenoviral vectors for cancer therapy. Cancers (Basel). 12:11392020. View Article : Google Scholar | |
|
Ip WH and Dobner T: Cell transformation by the adenovirus oncogenes E1 and E4. FEBS Lett. 594:1848–1860. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Bradley RR, Maxfield LF, Lynch DM, Iampietro MJ, Borducchi EN and Barouch DH: Adenovirus serotype 5-specific neutralizing antibodies target multiple hexon hypervariable regions. J Virol. 86:1267–1272. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Niemann J and Kuhnel F: Oncolytic viruses: Adenoviruses. Virus Genes. 53:700–706. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Machitani M, Katayama K, Sakurai F, Matsui H, Yamaguchi T, Suzuki T, Miyoshi H, Kawabata K and Mizuguchi H: Development of an adenovirus vector lacking the expression of virus-associated RNAs. J Control Release. 154:285–289. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Zheng Y, Stamminger T and Hearing P: E2F/Rb family proteins mediate interferon induced repression of adenovirus immediate early transcription to promote persistent viral infection. PLoS Pathog. 12:e10054152016. View Article : Google Scholar : PubMed/NCBI | |
|
Yamauchi S, Zhong B, Kawamura K, Yang S, Kubo S, Shingyoji M, Sekine I, Tada Y, Tatsumi K, Shimada H, et al: Cytotoxicity of replication-competent adenoviruses powered by an exogenous regulatory region is not linearly correlated with the viral infectivity/gene expression or with the E1A-activating ability but is associated with the p53 genotypes. BMC Cancer. 17:6222017. View Article : Google Scholar : PubMed/NCBI | |
|
Cervera-Carrascon V, Quixabeira DCA, Havunen R, Santos JM, Kutvonen E, Clubb JHA, Siurala M, Heiniö C, Zafar S, Koivula T, et al: Comparison of clinically relevant oncolytic virus platforms for enhancing T cell therapy of solid tumors. Mol Ther Oncolytics. 17:47–60. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Huang H, Liu Y, Liao W, Cao Y, Liu Q, Guo Y, Lu Y and Xie Z: Oncolytic adenovirus programmed by synthetic gene circuit for cancer immunotherapy. Nat Commun. 10:48012019. View Article : Google Scholar : PubMed/NCBI | |
|
Rosewell Shaw A and Suzuki M: Recent advances in oncolytic adenovirus therapies for cancer. Curr Opin Virol. 21:9–15. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Ran L, Tan X, Li Y, Zhang H, Ma R, Ji T, Dong W, Tong T, Liu Y, Chen D, et al: Delivery of oncolytic adenovirus into the nucleus of tumorigenic cells by tumor microparticles for virotherapy. Biomaterials. 89:56–66. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Tazawaa H, Kagawab S and Fujiwarab T: Oncolytic adenovirus-induced autophagy: Tumor-suppressive effect and molecular basis. Acta Med Okayama. 67:333–342. 2013.PubMed/NCBI | |
|
Freedman JD, Duffy MR, Lei-Rossmann J, Muntzer A, Scott EM, Hagel J, Campo L, Bryant RJ, Verrill C, Lambert A, et al: An oncolytic virus expressing a T-cell engager simultaneously targets cancer and immunosuppressive stromal cells. Cancer Res. 78:6852–6865. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Jung KH, Choi IK, Lee HS, Yan HH, Son MK, Ahn HM, Hong J, Yun CO and Hong SS: Oncolytic adenovirus expressing relaxin (YDC002) enhances therapeutic efficacy of gemcitabine against pancreatic cancer. Cancer Lett. 396:155–166. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Yokoda RT, Nagalo BM and Borad MJ: Oncolytic adenoviruses in gastrointestinal cancers. Biomedicines. 6:332018. View Article : Google Scholar | |
|
Quail DF and Joyce JA: Microenvironmental regulation of tumor progression and metastasis. Nat Med. 19:1423–1437. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Belli C, Trapani D, Viale G, D'Amico P, Duso BA, Della Vigna P, Orsi F and Curigliano G: Targeting the microenvironment in solid tumors. Cancer Treat Rev. 65:22–32. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Zhong S, Jeong JH, Chen Z, Chen Z and Luo JL: Targeting tumor microenvironment by small-molecule inhibitors. Transl Oncol. 13:57–69. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Terren I, Orrantia A, Vitalle J, Zenarruzabeitia O and Borrego F: NK cell metabolism and tumor microenvironment. Front Immunol. 10:22782019. View Article : Google Scholar : PubMed/NCBI | |
|
Maimela NR, Liu S and Zhang Y: Fates of CD8+ T cells in tumor microenvironment. Comput Struct Biotechnol J. 17:1–13. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Najafi M, Farhood B and Mortezaee K: Extracellular matrix (ECM) stiffness and degradation as cancer drivers. J Cell Biochem. 120:2782–2790. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Guo S and Deng CX: Effect of stromal cells in tumor microenvironment on metastasis initiation. Int J Biol Sci. 14:2083–2093. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Jang I and Beningo KA: Integrins, CAFs and mechanical forces in the progression of cancer. Cancers (Basel). 11:7212019. View Article : Google Scholar | |
|
Jarosz-Biej M, Smolarczyk R, Cichon T and Kulach N: Tumor microenvironment as A ‘Game Changer’ in cancer radiotherapy. Int J Mol Sci. 20:32122019. View Article : Google Scholar | |
|
Nishide S, Uchida J, Matsunaga S, Tokudome K, Yamaguchi T, Kabei K, Moriya T, Miura K, Nakatani T and Tomita S: Prolyl-hydroxylase inhibitors reconstitute tumor blood vessels in mice. J Pharmacol Sci. 143:122–126. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Carretero R, Sektioglu IM, Garbi N, Salgado OC, Beckhove P and Hammerling GJ: Eosinophils orchestrate cancer rejection by normalizing tumor vessels and enhancing infiltration of CD8(+) T cells. Nat Immunol. 16:609–617. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Zhao H, Tian X, He L, Li Y, Pu W, Liu Q, Tang J, Wu J, Cheng X, Liu Y, et al: Apj+ vessels drive tumor growth and represent a tractable therapeutic target. Cell Rep. 25:1241–1254.e5. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Brand A, Singer K, Koehl GE, Kolitzus M, Schoenhammer G, Thiel A, Matos C, Bruss C, Klobuch S, Peter K, et al: LDHA-Associated lactic acid production blunts tumor immunosurveillance by T and NK cells. Cell Metab. 24:657–671. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Fischer K, Hoffmann P, Voelkl S, Meidenbauer N, Ammer J, Edinger M, Gottfried E, Schwarz S, Rothe G, Hoves S, et al: Inhibitory effect of tumor cell-derived lactic acid on human T cells. Blood. 109:3812–3819. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Colegio OR, Chu NQ, Szabo AL, Chu T, Rhebergen AM, Jairam V, Cyrus N, Brokowski CE, Eisenbarth SC, Phillips GM, et al: Functional polarization of tumour-associated macrophages by tumour-derived lactic acid. Nature. 513:559–563. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Ohashi T, Aoki M, Tomita H, Akazawa T, Sato K, Kuze B, Mizuta K, Hara A, Nagaoka H, Inoue N and Ito Y: M2-like macrophage polarization in high lactic acid-producing head and neck cancer. Cancer Sci. 108:1128–1134. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Urbanska K and Orzechowski A: Unappreciated role of LDHA and LDHB to control apoptosis and autophagy in tumor cells. Int J Mol Sci. 20:20852019. View Article : Google Scholar | |
|
Fleming V, Hu X, Weber R, Nagibin V, Groth C, Altevogt P, Utikal J and Umansky V: Targeting myeloid-derived suppressor cells to bypass tumor-induced immunosuppression. Front Immunol. 9:3982018. View Article : Google Scholar : PubMed/NCBI | |
|
Hinshaw DC and Shevde LA: The tumor microenvironment innately modulates cancer progression. Cancer Res. 79:4557–4566. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Safarzadeh E, Orangi M, Mohammadi H, Babaie F and Baradaran B: Myeloid-derived suppressor cells: Important contributors to tumor progression and metastasis. J Cell Physiol. 233:3024–3036. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Dysthe M and Parihar R: Myeloid-Derived suppressor cells in the tumor microenvironment. Adv Exp Med Biol. 1224:117–140. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Ribatti D, Tamma R and Crivellato E: Cross talk between natural killer cells and mast cells in tumor angiogenesis. Inflamm Res. 68:19–23. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Albini A, Bruno A, Noonan DM and Mortara L: Contribution to tumor angiogenesis from innate immune cells within the tumor microenvironment: Implications for immunotherapy. Front Immunol. 9:5272018. View Article : Google Scholar : PubMed/NCBI | |
|
Kabiraj A, Jaiswal R, Singh A, Gupta J, Singh A and Samadi FM: Immunohistochemical evaluation of tumor angiogenesis and the role of mast cells in oral squamous cell carcinoma. J Cancer Res Ther. 14:495–502. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Shee K, Yang W, Hinds JW, Hampsch RA, Varn FS, Traphagen NA, Patel K, Cheng C, Jenkins NP, Kettenbach AN, et al: Therapeutically targeting tumor microenvironment-mediated drug resistance in estrogen receptor-positive breast cancer. J Exp Med. 215:895–910. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Binnewies M, Roberts EW, Kersten K, Chan V, Fearon DF, Merad M, Coussens LM, Gabrilovich DI, Ostrand-Rosenberg S, Hedrick CC, et al: Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat Med. 24:541–550. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
de Sostoa J, Fajardo CA, Moreno R, Ramos MD, Farrera-Sal M and Alemany R: Targeting the tumor stroma with an oncolytic adenovirus secreting a fibroblast activation protein-targeted bispecific T-cell engager. J Immunother Cancer. 7:192019. View Article : Google Scholar : PubMed/NCBI | |
|
Lang FF, Conrad C, Gomez-Manzano C, Yung WKA, Sawaya R, Weinberg JS, Prabhu SS, Rao G, Fuller GN, Aldape KD, et al: Phase I Study of DNX-2401 (Delta-24-RGD) Oncolytic Adenovirus: Replication and immunotherapeutic effects in recurrent malignant glioma. J Clin Oncol. 36:1419–1427. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Havunen R, Siurala M, Sorsa S, Grönberg-Vähä-Koskela S, Behr M, Tähtinen S, Santos JM, Karell P, Rusanen J, Nettelbeck DM, et al: Oncolytic adenoviruses armed with tumor necrosis factor alpha and interleukin-2 enable successful adoptive cell therapy. Mol Ther Oncolytics. 4:77–86. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Santos JM, Cervera-Carrascon V, Havunen R, Zafar S, Siurala M, Sorsa S, Anttila M, Kanerva A and Hemminki A: Adenovirus coding for interleukin-2 and tumor necrosis factor alpha replaces lymphodepleting chemotherapy in adoptive T cell therapy. Mol Ther. 26:2243–2254. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Lee YS and Radford KJ: The role of dendritic cells in cancer. Int Rev Cell Mol Biol. 348:123–178. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Palucka K and Banchereau J: Cancer immunotherapy via dendritic cells. Nat Rev Cancer. 12:265–277. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Parnas O, Jovanovic M, Eisenhaure TM, Herbst RH, Dixit A, Ye CJ, Przybylski D, Platt RJ, Tirosh I, Sanjana NE, et al: A genome-wide CRISPR screen in primary immune cells to dissect regulatory networks. Cell. 162:675–686. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Oh DS and Lee HK: Autophagy protein ATG5 regulates CD36 expression and anti-tumor MHC class II antigen presentation in dendritic cells. Autophagy. 15:2091–2106. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Chen L, Hasni MS, Jondal M and Yakimchuk K: Modification of anti-tumor immunity by tolerogenic dendritic cells. Autoimmunity. 50:370–376. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Karnell JL, Rieder SA, Ettinger R and Kolbeck R: Targeting the CD40-CD40L pathway in autoimmune diseases: Humoral immunity and beyond. Adv Drug Deliv Rev. 141:92–103. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Vitale LA, Thomas LJ, He LZ, O'Neill T, Widger J, Crocker A, Sundarapandiyan K, Storey JR, Forsberg EM, Weidlick J, et al: Development of CDX-1140, an agonist CD40 antibody for cancer immunotherapy. Cancer Immunol Immunother. 68:233–245. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Zafar S, Sorsa S, Siurala M, Hemminki O, Havunen R, Cervera-Carrascon V, Santos JM, Wang H, Lieber A, De Gruijl T, et al: CD40L coding oncolytic adenovirus allows long-term survival of humanized mice receiving dendritic cell therapy. Oncoimmunology. 7:e14908562018. View Article : Google Scholar : PubMed/NCBI | |
|
Eriksson E, Milenova I, Wenthe J, Moreno R, Alemany R and Loskog A: IL-6 signaling blockade during CD40-mediated immune activation favors antitumor factors by reducing TGF-β, collagen type I, and PD-L1/PD-1. J Immunol. 202:787–798. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Guo X, Ding C, Lu J, Zhou T, Liang T, Ji Z, Xie P, Liu X and Kang Q: HP-NAP ameliorates OXA-induced atopic dermatitis symptoms in mice. Immunopharmacol Immunotoxicol. 42:416–422. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Codolo G, Fassan M, Munari F, Volpe A, Bassi P, Rugge M, Pagano F, D'Elios MM and de Bernard M: HP-NAP inhibits the growth of bladder cancer in mice by activating a cytotoxic Th1 response. Cancer Immunol Immunother. 61:31–40. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
D'Elios MM, Amedei A, Cappon A, Del Prete G and de Bernard M: The neutrophil-activating protein of Helicobacter pylori (HP-NAP) as an immune modulating agent. FEMS Immunol Med Microbiol. 50:157–164. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Ramachandran M, Jin C, Yu D, Eriksson F and Essand M: Vector-encoded Helicobacter pylori neutrophil-activating protein promotes maturation of dendritic cells with Th1 polarization and improved migration. J Immunol. 193:2287–2296. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Mantovani A, Marchesi F, Malesci A, Laghi L and Allavena P: Tumour-associated macrophages as treatment targets in oncology. Nat Rev Clin Oncol. 14:399–416. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Ubil E, Caskey L, Holtzhausen A, Hunter D, Story C and Earp HS: Tumor-secreted Pros1 inhibits macrophage M1 polarization to reduce antitumor immune response. J Clin Invest. 128:2356–2369. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Myers KV, Amend SR and Pienta KJ: Targeting Tyro3, Axl and MerTK (TAM receptors): Implications for macrophages in the tumor microenvironment. Mol Cancer. 18:942019. View Article : Google Scholar : PubMed/NCBI | |
|
Huang YJ, Yang CK, Wei PL, Huynh TT, Whang-Peng J, Meng TC, Hsiao M, Tzeng YM, Wu AT and Yen Y: Ovatodiolide suppresses colon tumorigenesis and prevents polarization of M2 tumor-associated macrophages through YAP oncogenic pathways. J Hematol Oncol. 10:602017. View Article : Google Scholar : PubMed/NCBI | |
|
Cho H, Seo Y, Loke KM, Kim SW, Oh SM, Kim JH, Soh J, Kim HS, Lee H, Kim J, et al: Cancer-Stimulated CAFs enhance monocyte differentiation and protumoral TAM activation via IL6 and GM-CSF secretion. Clin Cancer Res. 24:5407–5421. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Kuryk L, Moller AW, Garofalo M, Cerullo V, Pesonen S, Alemany R and Jaderberg M: Antitumor-specific T-cell responses induced by oncolytic adenovirus ONCOS-102 (AdV5/3-D24-GM-CSF) in peritoneal mesothelioma mouse model. J Med Virol. 90:1669–1673. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Hayat SMG, Biancon V, Pirro M, Jaafari MR, Hatamipour M and Sahebkar A: CD47 role in the immune system and application to cancer therapy. Cell Oncol (Dordr.). 43:19–30. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Huang Y, Lv SQ, Liu PY, Ye ZL, Yang H, Li LF, Zhu HL, Wang Y, Cui LZ, Jiang DQ, et al: A SIRPα-Fc fusion protein enhances the antitumor effect of oncolytic adenovirus against ovarian cancer. Mol Oncol. 14:657–668. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang KL, Li RP, Zhang BP, Gao ST, Li B, Huang CJ, Cao R, Cheng JY, Xie XD, Yu ZH and Feng XY: Efficacy of a new oncolytic adenovirus armed with IL-13 against oral carcinoma models. Onco Targets Ther. 12:6515–6523. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Scott EM, Jacobus EJ, Lyons B, Frost S, Freedman JD, Dyer A, Khalique H, Taverner WK, Carr A, Champion BR, et al: Bi- and tri-valent T cell engagers deplete tumour-associated macrophages in cancer patient samples. J Immunother Cancer. 7:3202019. View Article : Google Scholar : PubMed/NCBI | |
|
Yao C, Ni Z, Gong C, Zhu X, Wang L, Xu Z, Zhou C, Li S, Zhou W, Zou C and Zhu S: Rocaglamide enhances NK cell-mediated killing of non-small cell lung cancer cells by inhibiting autophagy. Autophagy. 14:1831–1844. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Davis MR, Zhu Z, Hansen DM, Bai Q and Fang Y: The role of IL-21 in immunity and cancer. Cancer Lett. 358:107–114. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Li Y, Li YF, Si CZ, Zhu YH, Jin Y, Zhu TT, Liu MY and Liu GY: CCL21/IL21-armed oncolytic adenovirus enhances antitumor activity against TERT-positive tumor cells. Virus Res. 220:172–178. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Rhode PR, Egan JO, Xu W, Hong H, Webb GM, Chen X, Liu B, Zhu X, Wen J, You L, et al: Comparison of the superagonist complex, ALT-803, to IL15 as cancer immunotherapeutics in animal models. Cancer Immunol Res. 4:49–60. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Yan Y, Li S, Jia T, Du X, Xu Y, Zhao Y, Li L, Liang K, Liang W, Sun H and Li R: Combined therapy with CTL cells and oncolytic adenovirus expressing IL-15-induced enhanced antitumor activity. Tumour Biol. 36:4535–4543. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Kubo N, Araki K, Kuwano H and Shirabe K: Cancer-associated fibroblasts in hepatocellular carcinoma. World J Gastroenterol. 22:6841–6850. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Chen X and Song E: Turning foes to friends: Targeting cancer-associated fibroblasts. Nat Rev Drug Discov. 18:99–115. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Feig C, Jones JO, Kraman M, Wells RJ, Deonarine A, Chan DS, Connell CM, Roberts EW, Zhao Q, Caballero OL, et al: Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer. Proc Natl Acad Sci USA. 110:20212–20217. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Erdogan B, Ao M, White LM, Means AL, Brewer BM, Yang L, Washington MK, Shi C, Franco OE, Weaver AM, et al: Cancer-associated fibroblasts promote directional cancer cell migration by aligning fibronectin. J Cell Biol. 216:3799–3816. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Erdogan B and Webb DJ: Cancer-associated fibroblasts modulate growth factor signaling and extracellular matrix remodeling to regulate tumor metastasis. Biochem Soc Trans. 45:229–236. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Arwert EN, Milford EL, Rullan A, Derzsi S, Hooper S, Kato T, Mansfield D, Melcher A, Harrington KJ and Sahai E: STING and IRF3 in stromal fibroblasts enable sensing of genomic stress in cancer cells to undermine oncolytic viral therapy. Nat Cell Biol. 22:758–766. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Puig-Saus C, Gros A, Alemany R and Cascallo M: Adenovirus i-leader truncation bioselected against cancer-associated fibroblasts to overcome tumor stromal barriers. Mol Ther. 20:54–62. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Jing Y, Chavez V, Ban Y, Acquavella N, El-Ashry D, Pronin A, Chen X and Merchan JR: Molecular effects of stromal-selective targeting by uPAR-retargeted oncolytic virus in breast cancer. Mol Cancer Res. 15:1410–1420. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Czekierdowska S, Stachowicz N, Chrosciel M and Czekierdowski A: Proliferation and maturation of intratumoral blood vessels in women with malignant ovarian tumors assessed with cancer stem cells marker nestin and platelet derived growth factor PDGF-B. Ginekol Pol. 88:120–128. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Wang R, Chadalavada K, Wilshire J, Kowalik U, Hovinga KE, Geber A, Fligelman B, Leversha M, Brennan C and Tabar V: Glioblastoma stem-like cells give rise to tumour endothelium. Nature. 468:829–833. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Wang S, Aurora AB, Johnson BA, Qi X, McAnally J, Hill JA, Richardson JA, Bassel-Duby R and Olson EN: The endothelial-specific microRNA miR-126 governs vascular integrity and angiogenesis. Dev Cell. 15:261–271. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Feng SD, Mao Z, Liu C, Nie YS, Sun B, Guo M and Su C: Simultaneous overexpression of miR-126 and miR-34a induces a superior antitumor efficacy in pancreatic adenocarcinoma. Onco Targets Ther. 10:5591–5604. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Harada A, Uchino J, Harada T, Nakagaki N, Hisasue J, Fujita M and Takayama K: Vascular endothelial growth factor promoter-based conditionally replicative adenoviruses effectively suppress growth of malignant pleural mesothelioma. Cancer Sci. 108:116–123. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Chen QN, Chen X, Chen ZY, Nie FQ, Wei CC, Ma HW, Wan L, Yan S, Ren SN and Wang ZX: Long intergenic non-coding RNA 00152 promotes lung adenocarcinoma proliferation via interacting with EZH2 and repressing IL24 expression. Mol Cancer. 16:172017. View Article : Google Scholar : PubMed/NCBI | |
|
Zhuo B, Wang R, Yin Y, Zhang H, Ma T, Liu F, Cao H and Shi Y: Adenovirus arming human IL-24 inhibits neuroblastoma cell proliferation in vitro and xenograft tumor growth in vivo. Tumour Biol. 34:2419–2426. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang Y and Zheng J: Functions of immune checkpoint molecules beyond immune evasion. Adv Exp Med Biol. 1248:201–226. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Li K and Tian H: Development of small-molecule immune checkpoint inhibitors of PD-1/PD-L1 as a new therapeutic strategy for tumour immunotherapy. J Drug Target. 27:244–256. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Kurachi M, Barnitz RA, Yosef N, Odorizzi PM, DiIorio MA, Lemieux ME, Yates K, Godec J, Klatt MG, Regev A, et al: The transcription factor BATF operates as an essential differentiation checkpoint in early effector CD8+ T cells. Nat Immunol. 15:373–383. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Deng J, Wang ES, Jenkins RW, Li S, Dries R, Yates K, Chhabra S, Huang W, Liu H, Aref AR, et al: CDK4/6 inhibition augments antitumor immunity by enhancing T-cell activation. Cancer Discov. 8:216–233. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Johnson DB, Sullivan RJ and Menzies AM: Immune checkpoint inhibitors in challenging populations. Cancer. 123:1904–1911. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang Y, Zhang H, Wei M, Mou T, Shi T, Ma Y, Cai X, Li Y, Dong J and Wei J: Recombinant adenovirus expressing a soluble fusion protein PD-1/CD137L subverts the suppression of CD8+ T cells in HCC. Mol Ther. 27:1906–1918. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Du T, Shi G, Li YM, Zhang JF, Tian HW, Wei YQ, Deng H and Yu DC: Tumor-specific oncolytic adenoviruses expressing granulocyte macrophage colony-stimulating factor or anti-CTLA4 antibody for the treatment of cancers. Cancer Gene Ther. 21:340–348. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Dias JD, Hemminki O, Diaconu I, Hirvinen M, Bonetti A, Guse K, Escutenaire S, Kanerva A, Pesonen S, Löskog A, et al: Targeted cancer immunotherapy with oncolytic adenovirus coding for a fully human monoclonal antibody specific for CTLA-4. Gene Ther. 19:988–998. 2012. View Article : Google Scholar : PubMed/NCBI |
